Please login to the form below

Not currently logged in
Email:
Password:

Valeant counters Paladin's bid for Afexa

Valeant Pharmaceuticals has increased its offer to acquire Afexa Life Sciences to $0.85 per common share in response to a rival bid from Paladin Labs.

Valeant Pharmaceuticals has increased its offer to acquire Afexa Life Sciences to $0.85 per common share in response to a rival bid from Paladin Labs.

Canada-based Valeant's latest offer is an increase of 20 per cent from the $0.71 per share originally offered under an agreement announced in August, 2011.

Paladin, a speciality pharmaceutical company also based in Canada, made an offer of $0.81 per share in September, 2011.

Michael Pearson, chairman and CEO of Valeant said the company was prepared to make the increased bid as Valeant would be able to make a bigger return on the investment than Paladin due to its greater size and global interests.

He said: "While we normally don't participate in an auction process, given that our existing offer has the full support of the board and management of Afexa, we felt it was appropriate to continue to respond quickly to Paladin's hostile overtures."

Afexa's main product is Cold-FX – Canada's leading over-the-counter flu remedy. The company's pipeline includes a children's version of the drug as well as treatments for chronic lymphocytic  leukaemia, cholesterol and diabetes.

27th September 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
90TEN Healthcare

90TEN is an award-winning healthcare communications consultancy that puts people at the heart of everything we do. Our Life.Changing. campaigns...

Latest intelligence

ema1
The European Medicines Agency: PRIME’d for access?
Leela Barham examines the impact of the EMA's PRIME fast track system after two years...
How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...

Infographics